



Clinical Audit Awareness Week 2025

Webinar and Q&A: Data-driven improvements in maternity care
A Regional Medical Director's perspective

Thursday 5 June 2025, 2.15pm - 3.00pm

This event will start at 2.15pm

Dr Edward Morris CBE FRCOG Regional Medical Director & Chief Clinical Information Officer NHS England (East of England Region)

Tina Strack Associate Director, National Clinical Audit and Patient Outcomes Programme (NCAPOP), HQIP








Welcome & introduction



- Welcome to Clinical Audit Awareness Week 2025 (2-6 June 2025)
- More info: www.hqip.org.uk/clinical-audit-awareness-week
- Introduction to today's topic








A Brief History from my CV

- NHS O&G Consultant from 2001 Norwich (Trained in London)
- RCOG President (2019-2022)
- RCOG Vice President (Clinical Quality) (2016-2019)
- Chair Clinical Quality Board (2016-2019), Member (2009-2016)
- Chair National Maternity and Perinatal Audit Project Board (2016-19)
- Co-Investigator, Each Baby Counts (2016-2019)
- Guideline Committee (2016-2019)
- Nice Guideline Alliance Consortium Board (2016-2019)
- Chair, RCOG Safety and Quality Committee (2009-2013)
- NCEPOD Steering Group 2010-2016
- NHSE HQIP Independent Advisory Group (Women & Children) (2014-2025)
- Vice Chair, Clinical Standards, Academy of Medical Royal Colleges (2020-2022)





My Current Role

• The Regional Medical Director (RMD) in NHS England is a key leadership role responsible for providing clinical leadership, advice, and support within a specific region, focusing on improving quality and safety of patient care, and driving transformation. They play a vital role in overseeing clinical commissioning, ensuring workforce resilience, and supporting trusts facing challenges.









Current Maternity Leaders in NHSE

- National
- National Chief Midwife Kate Brintworth
- National Clinical Director Donald Peebles
- Regional (NHSE East of England)
- Regional Chief Midwife Wendy Matthews
- Regional Lead Obstetrician Tejinder Kumar









Current Maternity Support System in NHSE

- National
- Maternity and Neonatal Board
- Maternity Quality, Performance and Surveillance committee
- Direct Support
- Maternity Service Support Programme via Regional teams
- Early Warning System (In Development)





Why the Interest in Maternity Safety?

- Numerous maternity investigations
 - Morecambe Bay
 - Cwm Taf
 - Shrewsbury and Telford
 - East Kent
 - **Nottingham**



Why Bruce Willis is quitting acting



Childbirth 'is not safe for women in England'

Mothers and babies died avoidably in NHS scandal

nity acnotal are implemented in full. is author has said.

Domas Okenden said hat many of the hospital Nits Trust were not unique. Her fire-year investigation, which begott a Nits Trust were not unique. Her fire-year investigation, which believes a miner mothers had deal would and the said and the said

Instead of investigating or learning from mistakes, the Shropshire trust had tended "to blame mothers"... in some cases even for their own deaths". Rhiannon Davies and Richard Stanton, whose daughter Kate died hours after her birth in March 2009, led calls for an inquiry. "All we ever wanted was to understand why Kate died." Davies ounderstand why kate died. Davies and, T begun to ak, questions but we may be used to be

Eleanor Hayward
Health Corespondent
Wemen in England are not safe in
childforth until the recommendations
of a report on the NHSs worst materauther has said. Deman Ockenden said that many of
the fallurs all Krewsbory and fellow of
the dark in the control to t

the afarm. These included the Care Quality Commission, responsible for regulating the NHS in England which read the commission responsible for regulating the NHS in England which was the commission of the NHS and the NHS a

requiring improvement, meaning they do not meet safety standards. There is now a shortage of 2,000 midwives. Ockenden called for 15 "immediate and essential" actions across all NHS

maternity units in a "blueprint" for sat care. They focused on staff number training, listening to families and im proving how hospitals investigate an learn from serious incidents. "Withou this, maternity services cannot provide

Putin faces revolt over blunders in Ukraine

war in Okrane as his advise him about the campaigns fal British spy chief will say today. Sir Jeremy Fleming, the dir GCHQ, will outline how the

hort of weapons and morale". Intelligence shared with British sp encies has pointed to Russian troop using to carry out orders, sabotag Officials in Washington said tha Putin "didn't even know his militar; was using and losing conscripts ... showing a clear breakdown in the flov

Mr Shane Warne

'Isis Beatle' on trial

Oldest star spotted











"Big data" in Maternity





Maternal, Newborn and Infant Clinical Outcome **Review Programme**



Saving Lives, Improving Mothers' Care

Lessons learned to inform future maternity care from the UK and Ireland Confidential Enquiries into Maternal Deaths and Morbidity 2009-2012



December 2014





















each baby COUNTS •

Each Baby Counts is the RCOG's national quality improvement programme with the aim:

"To reduce the number of babies who die or are left severely disabled as a result of incidents occurring during term labour by 50% by 2020"




@eachbabycounts








Each Baby Counts Would different care have changed the outcome?





Each Baby Counts Key Themes













National Maternity & Perinatal Audit

- A large scale audit of the NHS maternity services across England, Scotland and Wales
- Using timely, high quality data, the audit evaluates a range of care processes and outcomes in order to identify good practice and areas for improvement in the care of women and babies looked after by NHS maternity services


















Haemorrhage of 1500 ml or more












Stillbirth & Neonatal Mortality – the National Ambition

Stillbirths and neonatal mortality rates, England, 2010 to 2023



Source: Child and Infant Mortality in England and Wales, 2023 from the Office for National Statistics








MBRRACE - 2025

Rates of baby death continued to decrease in 2023, mostly because of a reduction in stillbirths

Compared to 2022, stillbirth rates were lower in every nation of the UK, and fewer newborns died in England, Wales, and Northern Ireland. However, changes over a single year don't always tell the whole story, so it's important to look at trends over a longer period of time.

Since MBRRACE-UK started in 2013, the number of babies who died shortly before, during, or soon after birth has been falling. In 2023, the rate was 4.84 baby deaths for every 1,000 births. This is 20% lower than in 2013, mostly because there were fewer stillbirths.

Extended perinatal deaths






2022 Country 2023 UK & Crown 5.04 4.84 **V Dependencies England** 5.00 4.88 4.90 4.56 **V** Scotland 5.54 Wales 5.10 Northern Ireland 5.78 4.16 **V**

Stillbirths

per 1,000 total births



Country	2022	2023
UK & Crown Dependencies	3.35	3.22 ▼
England	3.33	3.27 ▼
Scotland	3.31	2.95 🔻
Wales	3.63	3.32 ▼
Northern Ireland	3.49	2.51 🔻

Neonatal deaths

per 1,000 live births

1.84	11% lower than in 2013
1.04	1.63

Country	2022	2023
UK & Crown Dependencies	1.69	1.63 ▼
England	1.67	1.62 ▼
Scotland	1.59	1.61
Wales	1.91	1.79 ▼
Northern Ireland	2.29	1.66 ▼







Stillbirths per 1,000 total births

Gestational age	2022	2023
22 to 23 weeks	405.5	403.0 ▼
24 to 27 weeks	216.0	207.8 ▼
28 to 31 weeks	74.4	69.9 ▼
32 to 36 weeks	12.7	12.5 ▼
37 to 41 weeks	1.09	0.99 ▼

Neonatal deaths per 1,000 live births

Gestational age	2022	2023
22 to 23 weeks	625.2	641.1 🔺
24 to 27 weeks	139.6	146.1 🔺
28 to 31 weeks	29.5	31.1 🔺
32 to 36 weeks	6.58	5.05 ▼
37 to 41 weeks	0.62	0.60 🔻

Stillbirth rates decreased, but neonatal mortality rates increased for the most preterm babies


Stillbirth rates dropped across all stages of pregnancy, with the biggest decrease seen in babies born at term (37 to 41 weeks). However, neonatal deaths increased for babies born very prematurely, between 24 and 31 weeks, but decreased for those born at 32 weeks or later.

Babies born at 22 to 23 weeks made up a growing share (25%) of all neonatal deaths.

Preterm births remained a major factor in baby deaths, with 76% of stillbirths and 75% of neonatal deaths happening in babies born before 37 weeks.



Ethnicity




Data sources: MBRRACE-UK, PDS, ONS, NRS, PHS, NIMATS, States of Guernsey, States of Jersey.







Deprivation




Data sources: MBRRACE-UK, PDS, ONS, NRS, PHS, NIMATS, States of Guernsey, States of Jersey.







Combined Deprivation and Ethnicity









Turning Data Into Actions

What do we need to do?

These findings show that progress is being made in reducing baby deaths, but there is still important work to do—especially to

tackle the gaps linked to deprivation, ethnicity, and how early in pregnacy a baby is born.

MBRRACE-UK has previously made national recommendations to help with this, but local services, networks, and commissioners may need to take a closer look at their own areas to understand what's happening and take action that works for their communities.

1. Make sure services are planned and funded to meet the growing need for intensive care for extremely premature babies

Care commissioners should ensure that neonatal intensive care services have the capacity and resources to support the increasing number of babies born before 24 weeks who are receiving active care focused on survival.

2. Support thorough reviews of baby deaths to help improve care

All stillbirths and neonatal deaths across the UK should be reviewed with the Perinatal Mortality Review Tool (PMRT), with input from experienced external clinicians, so services can learn from them and improve how care is delivered.

3. Help healthcare providers use national guidance to improve care for premature babies

Royal Colleges and care commissioners should support healthcare providers to adopt and implement the BAPM Perinatal Optimisation Pathway, which aims to improve outcomes for preterm babies.

4. Keep taking targeted action to reduce health inequalities


Work should continue at both national and local levels to reduce the unfair differences in outcomes linked to factors like poverty, ethnicity, and where families live.









MBRRACE Maternal Deaths











Key messages

from the report 2024



275 women died during pregnancy or up to six weeks after pregnancy in 2020-2022 13.56 women per 100,000 died during pregnancy or up to six weeks after pregnancy



Causes of women's deaths



The national risk assessment tool must be

evidence-based, clear and



Risk happens early - define pathways so women who need medication to prevent blood clots can access it when they need it, including in the first trimester

Consider the effects of vomiting, dehydration, immobility and other symptoms that can increase risk

Blood clots 16%

38 women COVID-19 14%

43 women

25 women

Inequalities in maternal mortality



Asian women

Most deprived areas 21.28 per 100,000

maternities Age 35 and older

22.01 per 100.000 maternities

Overweight or obese 177/275 women

Multiple disadvantages 26/275 women

36 women Cardiac 13% disease Mental 31 women health conditions 11%

OCP313 370		
Epilepsy and stroke	9%	25 women
Other physical conditions	7%	20 women

Obstetric bleeding	7%	18 women
Early pregnancy disorders	5%	15 women
Other direct causes	4%	10 women
Cancer	3%	7 women
Pre-eclamosia	3%	7 women

Key messages

for the care of women with thrombosis and thromboembolism

Ensure women at high-risk of venous thromboembolism (VTE) receive pre-pregnancy counselling and are appropriately managed in the first trimester

Early risk assessment Assess VTE risk at the first opportunity

Pathways for advice Ensure GPs can obtain timely specialist advice



Pathways for referral

responsible for prescribing in

Access to thromboprophylaxis Clearly define who is

early pregnancy

Outline how to refer women at high-risk of VTE

Research evidence is needed to restructure the existing national VTE risk assessment tool

The national assessment tool should:



Be easy to use, clear and accurate



Take into account factors that may arise during pregnancy or in the postnatal period



Be based on research evidence

Women should be assessed:



At booking or as early in pregnancy as possible



After pregnancy, regardless of how the pregnancy ends



If they are admitted to the hospital or develop other problems



Evidence-based







A Real World Example......

- I was contacted by a medical director concerned by a run of adverse events within their hospital. He was concerned that perhaps a local intervention with clinical teams might be necessary but didn't want to without knowing if this would be the right thing to do.
- I obtained details of the cases, agreed that they were of concern and suggested some early things to do and promised to see if there was data to support an intervention or otherwise
- For this particular problem with this patient group I could not get reassurance from published papers or other leaders
- I remembered an HQIP database from which I could get the detail that suggested to me that the number of adverse events was above that normally expected and then worked with the MD on service improvements





So What Does This Data Add?

- Central collection of data:
 - Unbiased
 - Authoritative
 - Trusted
 - Influential
 - Less demand on the clinical front line
- Driver of improvements in:
 - Safety
 - Quality
 - Choice
 - Performance?






Thank you and over to Tina Strack







About HQIP











Maternal Newborn and Infant CORP

- 5 streams of work, split into:
 - Maternal mortality
 - Perinatal mortality
 - Surveillance
 - Confidential enquiries





MBRRACE – Impact and influencing change

External reviews ordered over trust's baby death rates

By Alison Moore | 29 May 2025

















- > National audit shows high mortality Leeds says it reflects very high risk and sick babies
- > CQC reports expected soon
- > Trust and NHSE commission external reviews

Two external reviews are being commissioned into maternity and neonatal care at the trust with the highest perinatal mortality rates.

Leeds Teaching Hospitals Trust has claimed its extended perinatal mortality rate – which measures stillbirths and neonatal deaths - is within the expected range, considering it takes many high-risk pregnancies, including some where babies are not expected to survive, as a specialist centre.

However, a report to its board meeting today reveals its chief medical officer, Magnus Harrison, is commissioning an external review of the issue.

The trust, one of the biggest in England, told HSJ the work was in the "very early stages". The review



Most popular

Most commented



New CEO named at trust facing calls for public



NHSE director: 50% cut to ICB costs 'may well not be right number'



Up to a third of ICBs to remain independent despite budget cut









Influencing change - Sepsis

2014 Report







Sepsis – case studies

A woman went to her GP in the first trimester with a sore throat. She had lymphadenopathy but no other assessment was made. She presented to the gynaecology department 24 hours later with diarrhoea and vomiting and feeling unwell. She was hypotensive and tachycardic. She was reviewed by a junior doctor almost three hours after admission who did not recognise the seriousness of her condition. The obstetric registrar reviewed her 6 hours following admission and prescribed antibiotics, which were not given for over an hour. When the seriousness of her condition was recognised she was transferred to another hospital for intensive care. Despite emergency surgery she died from overwhelming Group A Streptococcal sepsis.


A woman who was seven days post spontaneous vaginal delivery became unwell at home with a fever. She was advised to attend the maternity unit immediately. On admission she was noted to be tachycardic, tachypnoeic and febrile. She was prioritised for urgent medical review. A diagnosis of acute sepsis from retained products was made and fluid resuscitation started immediately. Intravenous antibiotics were started within one hour of the diagnosis and she was transferred to the high dependency unit. The retained products of conception were removed promptly and she made a full recovery. Blood culture subsequently grew Klebsiella. Early recognition, clear advice and prompt treatment led to a good outcome without any further complications.







Think Sepsis



Almost a quarter of women who died had Sepsis (severe infection).

Women with sepsis need:

- Early diagnosis
- · Rapid antibiotics
- Review by senior doctors and midwives

Prompt treatment and action can make the difference between life and death







Sepsis - Impacts

- NHS Education Scotland Maternal Sepsis e-Learning Package
- 60 minute e-learning package, featuring scenarios based on the vignettes included in the MBRRACE-UK 2014 report, to help improve identification and early management of maternal sepsis







Sepsis - Impacts

- NHS Education Scotland Maternal Sepsis e-Learning Package
- 60 minute e-learning package, featuring scenarios based on the vignettes included in the MBRRACE-UK 2014 report, to help improve identification and early management of maternal sepsis
- UK Sepsis Trust Clinical Toolkits





Sepsis

SEPSIS SCREENING TOOL ACUTE ASSESSMENT		PREGNANT OR UP TO 4 WEEKS POST-PREGNANCY	
PATIENT DETAILS:	DATE: NAME: Designation: Signature:	TIME:	
START THIS CHART IF THE PATIENT LOOKS UNWELL OR PHYSIOLOGY IS ABNORMAL e.g. MEWS RISK FACTORS FOR SEPSIS INCLUDE: Recent trauma / surgery / invasive procedure			
COULD THIS BE DUE TO LIKELY SOURCE: Respiratory Urine Breast abscess Abdominal pain / distension	nfected caesarean / perineal wound	SEPSIS UNLIKELY, CONSIDER OTHER DIAGNOSIS	
ANY RED FLAG PRESENT? Objective evidence of new or altered mental state Systolic BP ≤ 90 mmHg (or drop of >40 from norm Heart rate >130 per minute Respiratory rate ≥ 25 per minute New need for 02 (40% or more) to keep Sp02 > 92 >88% 60991 Non-blanching rash / mottled / ashen / cyanotic Lactate ≥ 2 mmol/t* Not passed urine in 18 hours (<0.5ml/kg/hr if catheter "lactate may be raised in & immediately after normal delive"	SEPS	FLAG PSIS IS SIX	
ANY AMBER FLAG PRESENT? Acute deterioration in functional ability Family report mental status change Respiratory rate 21-24 Heart rate 100-130 or new dysrhythmia Systotic BP 91-100 mmHg Has had invasive procedure in last 6 weeks leg. 05, forcepe delivers, EEPO, cerclage, CVs, miscerriage, termine Temperature < 36°C Has diabetes or impaired immunity Close contact with GAS Prolonged rupture of membranes	IMMEDIATE REVIEW IF ANTIMICROBIALS ADMINISTER AS 500 BUT ALWAYS WITHI I have prescribed antin YES This patient does no	ARE NEEDED, ON AS DECISION MADE N 3 HOURS icrobials t require antimicrobials as: nt has an infection propriate antimicrobials	
Wound infection Offensive vaginal discharge Not passed urine in 12-18 hr (0.5 ml/kg/hr to 1 ml/kg/catheterised) NO AMBER FLAGS = ROUTINE CARE / CONSIDER OTHER DIA Interpret physiology in context of individual patient	_	GRADE: TIME: THE UK	
	GNOSIS	SEPS TRU	

SEPSIS SCREENING TOOL - THE SEPSIS SIX		PREGNANT OR UP TO 2 WEEKS POST-PREGNANCY	
PATIENT DETAILS:		DATE: NAME: Designation: Signature:	TIME:
COMPLE	ETE ALL ACTI	ONS WITHIN	ONE HOUR
NOT ALL F	URE ST3+ ATTENDS PATIENTS WITH RED FLAGS WILL NEED THE TO DECISION MAKER MAY SEEK ALTERNATIVE TO GRADE:	SEPSIS 6' URGENTLY.	NT TIME
START IF	GEN IF REQUIRED 02 SATURATIONS LESS THAN 92% - AIM FOR OF HYPERCARBIA AIM FOR SATURATIONS O		TIME
BLOOD CU	D BLOODS INCLUDI ULTURES, VBG, BLOOD GLUCOSE, LACTATE, FI PUNCTURE IF INDICATED, CONSIDER RAPID P	BC, U&Es, LFTs, CRP AND CLOTTING	TIME
MAX. DOS CONSIDER EVALUATI	E IV ANTIBIOTICS, C E BROAD SPECTRIM THERAPY (CONSIDER ES ES: LOCAL POLICY / ALLERGY STATUS / ANTIVE E NEED FOR IMAGING/ SPECIALIST REVIEW T E TO DRAIMAGE ENSURE ACHIEVED ASAP BU	SCALATION IF ALREADY ON ANTIBIOTICS) RALS O HELP IDENTIFY SOURCE IF SOURCE	Y TIME
IF LACTAT	E IV FLUIDS TE > 2mmol/L OR SBP < 90 mmHg GIVE 500ml AT IF NO IMPROVEMENT.	Lover 15 min AND CALL	TIME
USE EARL	IITOR Y WARNING SCORE e.g. MEWS. MEASURE UR R. REPEAT LACTATE HOURLY IF INITIAL LACT	INARY OUTPUT: THIS MAY REQUIRE A URIN. TATE HIGH OR CLINICAL CONDITION CHANGE	TIME ARY
	AFTER ONE HOUR - at least every 30 mins u		
	DDITIONAL NOTES I lival of specialist teams, de-escalation of		baking.
paper, email attachment) are cons	nent is maintained by The UX Sepsis Trust. Any copies of this sedidened to have passed out of control and should be checked for 33 (Scotland) SCOSO277. Company registration number 864403	r currency and validity. The UK Sepsis Trust registered charit	I LOSI









Sepsis - Impacts


- NHS Education Scotland Maternal Sepsis e-Learning Package
- 60 minute e-learning package, featuring scenarios based on the vignettes included in the MBRRACE-UK 2014 report, to help improve identification and early management of maternal sepsis
- UK Sepsis Trust Clinical Toolkits
- Wales Guidelines and Standards







Sepsis











Pre-eclampsia and Aspirin Use

2019 Report identified pre-eclampsia as an issue

Women with risk factors for pre-eclampsia need aspirin to be prescribed from 12 weeks of pregnancy









Pre-eclampsia and Aspirin Use

- Recommendation:
- A national Patient Group Direction, including advice relating to safe, timely and costeffective local implementation, as a solution should be explored to ensure consistent high quality care by allowing midwives to supply aspirin to eligible women in line with NICE Guidance (MPG2, NG133).





Pre-eclampsia and Aspirin Use

Aspirin tablets for use within antenatal and maternity services

Published 9 February 2022 · Last updated 3 February 2025 · See all updates

Topics: Aspirin · Patient Group Directions · Safety in Pregnancy · Templates

SPS PGD template for the supply of aspirin tablets to individuals at risk of pre-eclampsia during pregnancy.

Provenance

Developed by SPS and NHS England, reviewed by the Royal College of Obstetrics and Gynaecology (RCOG), with the support of specialists working within clinical practice for medicines commonly supplied for the prevention of complications in pregnancy.

PGD template attachment

The template PGD is attached below to download and use in conjunction with our implementation advice.

M PMP Aspirin National PGD template V2.0 FINAL October 2024 · Word · 59 KB

More pregnancy and supportive medicines PGD templates

- Omeprazole for use within antenatal and maternity services
- Terbutaline injection for use in labour within maternity services
- Benzylpenicillin for Group B Streptococcus for use in neonates
- Folic acid 5mg tablets for use during pregnancy

All PGD templates

National PGD templates

National PGD templates are developed with experts for clinical specialties. They reduce duplication and variation, and improve consistency of care.









Pre-eclampsia and Aspirin

Insert logo of authorising body

This Patient Group Direction (PGD) must only be used by registered healthcare professionals who have been named and authorised by their organisation to practice under it. The most recent and in date final signed version of the PGD should be used.

PATIENT GROUP DIRECTION (PGD)

Supply of aspirin tablets for individuals at high risk of pre-eclampsia in location/service/organisation

Version Number 2.0

	Change History				
Version and	Change details				
Date					
Version 1	New template				
February 2022					
Version 2	Planned review. Updated SLWG membership.				
October 2024	Minor formatting changes. Watermark removed.				

Each organisation using this PGD must ensure that it is formally signed by a senior pharmacist, a senior doctor and any other professional group representatives involved in its review and that it is reviewed in line with the organisations' PGD governance system. The organisation's governance lead must sign to authorise the PGD on behalf of the authorising organisation to ensure that this document meets legal requirements for a PGD.

practise under it (See Appendix A). The most recent and in date final signed version of the PGD must be used.

PGD DEVELOPMENT GROUP

Date PGD template comes into effect:	1st February 2025
Review date	August 2027
Expiry date:	31st January 2028

This PGD template has been peer reviewed by the Preventative Medicines in Pregnancy PGDs Short Life Working Group in accordance with their Terms of Reference. It has been reviewed by the Royal College of Obstetrics and Gynaecology (RCOG) and has been endorsed by Professor Donald Peebles, National Clinical Director for Maternity NHS England.

This section MUST REMAIN when a PGD is adopted by an organisation.

Name	Designation	DATE	
Amy Moore	Pharmacist HIV, Sexual and Reproductive Health Kingston		
	Hospital NHS Foundation Trust		
Christina Nurmahi	Women & Newborn Care Group Lead Pharmacist,		
	University Hospital Southampton NHS Foundation Trust		
Emma Luhr	Director of Midwifery, Frimley Health NHS Foundation Trust	1	
Felipe Castro Cardona	Head of Midwifery Clinical Workforce		
-	Chief Midwifery Office, NHS England		
George Attilakos	Consultant in Fetal Medicine and Obstetrics in UCLH,	1	
_	Clinical Lead for Obstetrics and RCOG Council member		
Hannah Putley	Policy Manager - Maternity and Neonatal, NHS Quality,		
	Safety and Investigations, Department of Health and Social	October	
	Care	2024	
Jo Jenkins	Associate Director Medicines Governance Specialist		
	Pharmacy Service		
Rosie Furner (Working	Advanced Specialist Pharmacist - Patient Group Directions		
Group Co-ordinator)	and Medicines Mechanisms, Specialist Pharmacy Service		
Sandy Richards	BSW LMNS Midwife		
	NHS Bath and North East Somerset, Swindon and Wiltshire Integrated Care Board (ICB)		








So what? Has any of this made a difference?












2024 report












2024 report







Q&A













Upcoming Clinical Audit Awareness Week activities

• SIGN UP for tomorrow's Clinical Audit Heroes Awards COMMENDATIONS webinar on Fri 6 June, 10am – 11am

Find out who went he brand new NCAROR and Communicating for Impact

Find out who won the brand-new NCAPOP and Communicating for Impact Commendations

With HQIP's NCAPOP Associate Director, Rachael Sample

SIGN UP for tomorrow's Lunch & Learn on Fri 6 June, 12.30pm – 1.45pm
 Efficiencies
 With RCP's Dr Theresa Barnes, N-QI-CAN, and HQIP's CEO, Chris Gush

 Find out more about all #CAAW25 activities and releases (event recordings, resources, case studies etc)

Scan the QR code or go to: www.hqip.org.uk/clinical-audit-awareness-week

For those on social media, please share your #CAAW25 updates!










Tell us what you think...

Complete the short form to share your feedback about this #CAAW25 event



www.bit.ly/3S6D7LS











In collaboration with



Clinical Audit Awareness Week 2025 (#CAAW25)

DISCOVER MORE #CAAW25 EVENTS & RESOURCES

Go to www.hqip.org.uk/clinical-audit-awareness-week
Or scan the QR code



Stay in touch:

- Sign up to HQIP mailing list: www.hqip.org.uk/subscribe-form/
- Follow on X and LinkedIn: @HQIP (use the hashtag #CAAW25)
- Share your feedback about CAAW25 www.bit.ly/3S6D7LS



